Cash Flow Statement

Currency: CNY

	Jun-2021	Sep-2021	Dec-2021	Mar-2022	Jun-2022	Sep-2022	Dec-2022	Mar-2023	Jun-2023	Sep-2023	Dec-2023	Mar-2024
Operating Cash Flow
Cash Taxes Paid	(242)	(182)	(176)	(172)	(180)	(186)	(147)	(205)	(127)	(86)	(100)	(9)
Change in Working Capital	(634)	(537)	(649)	(823)	(889)	(1 018)	(1 194)	(1 293)	(1 329)	(1 263)	(1 043)	(886)
Cash from Operating Activities	1 112 N/A	583 -48%	617 +6%	453 -27%	440 -3%	445 +1%	735 +65%	553 -25%	649 +17%	589 -9%	153 -74%	181 +18%
Investing Cash Flow
Capital Expenditures	(297)	(268)	(262)	(576)	(731)	(812)	(963)	(681)	(523)	(437)	(233)	(168)
Other Items	(895)	(328)	(1 166)	(1 303)	(1 109)	(896)	10	(121)	273	(695)	(668)	299
Cash from Investing Activities	(1 192) N/A	(596) +50%	(1 428) -139%	(1 879) -32%	(1 840) +2%	(1 708) +7%	(952) +44%	(803) +16%	(250) +69%	(1 132) -353%	(901) +20%	131 N/A
Financing Cash Flow
Net Issuance of Debt	(51)	(25)	(40)	0	(31)	185	216	942	1 096	962	822	(174)
Cash Paid for Dividends	0	0	(4)	0	0	(126)	(132)	(135)	(647)	(534)	(533)	(538)
Other	292	(7)	2 114	0	1 997	0	(4)	0	(19)	(19)	(39)	(96)
Cash from Financing Activities	241 N/A	(32) N/A	2 070 N/A	0 N/A	1 961 N/A	2 177 +11%	79 -96%	802 +915%	551 -31%	409 -26%	250 -39%	(808) N/A
Change in Cash
Effect of Foreign Exchange Rates	(5)	(4)	(2)	(4)	(1)	(2)	5	7	8	8	1	1
Net Change in Cash	156 N/A	(49) N/A	1 256 N/A	649 -48%	559 -14%	912 +63%	(133) N/A	560 N/A	958 +71%	(126) N/A	(496) -294%	(495) +0%
Free Cash Flow
Free Cash Flow	814 N/A	315 -61%	355 +13%	(123) N/A	(291) -137%	(367) -26%	(228) +38%	(128) +44%	126 N/A	152 +20%	(80) N/A	12 N/A

Nanjing Vazyme Biotech Co Ltd
SSE:688105